Physician profile
John A Conti
NPI 1811973084
$6,691.03
in general payments reported to CMS, 2019-2025
55 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $601 · 2021: $334 · 2022: $545 · 2023: $774 · 2024: $866 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.52 |
| Education | $298.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,200.69 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Incyte Corporation | $582.46 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $429.21 | 2019-2025 | Keytruda, Keytruda Qlex |
| Genentech USA, INC. | $382.05 | 2019-2025 | Itovebi, Polivy |
| E.R. Squibb & Sons, L.L.C. | $364.40 | 2019-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $357.66 | 2019-2025 | Vyloy |
| Amgen INC. | $336.67 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Novartis Pharmaceuticals Corporation | $276.68 | 2019-2025 | |
| Eisai INC. | $199.98 | 2019-2022 | |
| Janssen Biotech, INC. | $176.40 | 2019-2025 | Darzalex, Talvey, Erleada |
| Karyopharm Therapeutics INC. | $161.22 | 2020-2025 | Xpovio |
| Lilly USA, LLC | $153.51 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Sun Pharmaceutical Industries INC. | $152.10 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.16 | 2019-2025 | Alunbrig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $102.73 | 2019-2023 | Libtayo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.